Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI343 + sintilimab + oxaliplatin + S-1
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IBI343 + sintilimab + oxaliplatin + S-1 is a multi-modality combination therapy regimen being developed by Innovent Biologics for the perioperative treatment of claudin 18.2 (CLDN18.2)-positive, resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. This regimen integrates IBI343, a recombinant humanized anti-CLDN18.2 antibody-drug conjugate (ADC) conjugated to an exatecan payload (a topoisomerase I inhibitor) via a cleavable linker, with sintilimab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). The combination also includes the SOX chemotherapy regimen, which consists of the platinum-based DNA cross-linker oxaliplatin and the oral fluoropyrimidine antimetabolite S-1. The therapeutic strategy aims to leverage the targeted cytotoxicity of the ADC, the immune checkpoint inhibition of sintilimab, and the systemic effects of chemotherapy to improve pathological complete response rates and survival outcomes in patients with CLDN18.2-expressing tumors.
- Other names
- IBI343 + sintilimab + SOX
02
Targets
Claudin 18.2DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on IBI343 + sintilimab + oxaliplatin + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI343 + sintilimab + oxaliplatin + S-1.